Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouzis
Summary: This retrospective study examined the clinical characteristics and efficacy of FTD/TPI in patients with metastatic colorectal cancer. The results showed that FTD/TPI is effective as a third-line treatment, regardless of mutational status and tumor sidedness, by prolonging progression-free survival and overall survival.
Article
Biochemistry & Molecular Biology
Joris van de Haar, Xuhui Ma, Salo N. Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, Nicoletta Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Maria Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F. A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri
Summary: Genomic analysis identified KRAS(G12) mutations as potential biomarkers of resistance to trifluridine/tipiracil treatment in metastatic colorectal cancer. Real-world data and phase 3 clinical trial data confirmed the significant association between KRAS(G12) mutations and reduced overall survival. These findings provide important implications for precision medicine in approximately 28% of patients with metastatic colorectal cancer.
Article
Multidisciplinary Sciences
Mamiko Shiroyama, Shota Fukuoka, Toshiki Masuishi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Yasuhiro Shimada, Taito Esaki, Akitaka Makiyama, Toshikazu Moriwaki
Summary: This study investigated the specific types of adverse events (AEs) associated with renal impairment in patients with metastatic colorectal cancer receiving trifluridine/tipiracil (FTD/TPI) treatment. The study found that moderate to severe renal impairment was significantly associated with an increased risk of grade 3 or higher neutropenia, but there was no significant increase in the risk of non-hematologic AEs in any of the groups. Overall survival and progression-free survival were comparable between patients with mild or moderate to severe renal impairment and those with normal renal function.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Yasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, Masato Nakamura, Jun Watanabe, Hitoshi Ojima, Akitaka Makiyama, Masahito Kotaka, Hiroki Hara, Yoshinori Kagawa, Naotoshi Sugimoto, Hisato Kawakami, Atsuo Takashima, Takeshi Kajiwara, Eiji Oki, Yu Sunakawa, Soichiro Ishihara, Hiroya Taniguchi, Takako Eguchi Nakajima, Satoshi Morita, Kuniaki Shirao, Naruhito Takenaka, Daisuke Ozawa, Takayuki Yoshino
Summary: This study assessed the noninferiority of trifluridine/tipiracil (FTD/TPI) plus bevacizumab as second-line treatment for metastatic colorectal cancer (mCRC) compared to fluoropyrimidine and irinotecan plus bevacizumab. The results showed that FTD/TPI plus bevacizumab did not demonstrate superiority over the control group in mCRC second-line treatment.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Keigo Chida, Daisuke Kotani, Yoshiaki Nakamura, Akihito Kawazoe, Yasutoshi Kuboki, Kohei Shitara, Takashi Kojima, Hiroya Taniguchi, Jun Watanabe, Itaru Endo, Takayuki Yoshino
Summary: The study demonstrated that patients treated with TAS102 plus BEV had longer overall survival and progression-free survival compared to those treated with TAS102 or regorafenib monotherapy. TAS102 plus BEV was independently associated with better OS and PFS on multivariate analysis, with no unexpected adverse events observed in any group.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Review
Medicine, General & Internal
Ioannis A. Voutsadakis
Summary: Trifluridine/tipiracil is a newer chemotherapy drug approved for the later-line treatment of metastatic colorectal and gastric cancers, showing a modest benefit in prolonging survival but with rare objective responses. Studies are seeking predictive biomarkers to identify patients who are more likely to benefit from the drug, with early neutropenia and ratios of leukocyte subsets being potential indicators. Combinations of laboratory values and clinical characteristics are also being examined for their predictive value in determining the efficacy of trifluridine/tipiracil treatment.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Fengxiang Huang, Haiyan Yang, Wenguang Bao, Yehong Bin, Shengsheng Zhou, Man Wang, Xiaoping Lv
Summary: The purpose of this meta-analysis is to evaluate the efficacy and safety of TAS-102 in treating metastatic colorectal cancer (mCRC) using the most recent data available. Through a systematic search of multiple databases, it was found that TAS-102 treatment resulted in longer overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), higher disease control rate (DCR), and did not increase the incidence of serious adverse events (SAEs).
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Nicholas Fidelman, Chloe E. E. Atreya, Madeline Griffith, M. Alexandra Milloy, Julia Carnevale, Pelin Cinar, Alan P. P. Venook, Katherine Van Loon
Summary: This study investigates the efficacy of combining TAS-102 with TARE for the treatment of chemotherapy-refractory metastatic colorectal cancer (mCRC) patients. The results demonstrate that the combination therapy is safe and consistently achieves disease control within the liver for patients with liver-dominant mCRC.
Article
Oncology
E. Van Cutsem, I Danielewicz, M. P. Saunders, P. Pfeiffer, G. Argiles, C. Borg, R. Glynne-Jones, C. J. A. Punt, A. J. Van de Wouw, M. Fedyanin, D. Stroyakovskiy, H. Kroening, P. Garcia-Alfonso, H. Wasan, A. Falcone, R. Fougeray, A. Egorov, N. Amellal, V Moiseyenko
Summary: The TASCO1 trial evaluated the use of trifluridine/tipiracil plus bevacizumab (TT-B) in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy, and the results showed that TT-B has potential therapeutic benefits.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Y. Kagawa, E. Shinozaki, R. Okude, T. Tone, Y. Kunitomi, M. Nakashima
Summary: This study evaluated the efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC) compared to FTD/TPI or regorafenib (REG) monotherapy. The real-world data showed that FTD/TPI+BEV was associated with longer overall survival (OS) and time to treatment discontinuation (TTD) compared to FTD/TPI or REG. This suggests that FTD/TPI+BEV could be a favorable regimen for refractory mCRC in clinical practice.
Article
Multidisciplinary Sciences
Ana Fernandez Montes, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Francisca Vazquez Rivera, Nieves Martinez Lago, Marta Covela Rua, Antia Cousillas Castineiras, Paula Gonzalez Villarroel, Juan De la Camara Gomez, Jose Carlos Mendez Mendez, Carmen Carriles Fernandez, Manuel Sanchez Canovas, Teresa Garcia Garcia
Summary: Trifluridine/tipiracil can improve overall survival in patients with refractory, metastatic colorectal cancer. The study validated prognostic factors from previous trials and nomograms, and developed an OS predictive model for this patient population. The results showed that the TAS-RECOSMO model was more accurate in predicting OS compared to other models.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Gianluca Arrichiello, Alessandra Perrone, Stefania Napolitano, Giulia Martini, Vincenzo De Falco, Pasquale Incoronato, Maria Maddalena Laterza, Gaetano Facchini, Vincenzo Famiglietti, Valeria Nacca, Fernando Paragliola, Rossella Napolitano, Gabriella Suarato, Antonella Nicastro, Erika Martinelli, Davide Ciardiello, Fortunato Ciardiello, Teresa Troiani
Summary: This study retrospectively observed the real-world application of the combination therapy of trifluridine-tipiracil and bevacizumab in Western mCRC patients. The results showed that this combination therapy exhibited certain activity and acceptable safety in mCRC patients.
Article
Oncology
Daniel Tong, Lei Wang, Jeewaka Mendis, Sharadah Essapen
Summary: A retrospective study of 56 patients with metastatic colorectal cancer receiving Lonsurf at a cancer center in the UK from 2016 to 2017 showed that Lonsurf offered improved PFS for some patients but inferior OS compared to clinical trial data. A subset of patients who received further systemic treatment after discontinuation of Lonsurf experienced additional OS benefit.
Article
Multidisciplinary Sciences
Nieves Martinez-Lago, Teresa Calleja Chucla, Beatriz Alonso De Castro, Rafael Varela Ponte, Cristina Reboredo Rendo, Martin Igor Gomez-Randulfe Rodriguez, Sofia Silva Diaz, Begona Grana Suarez, Juan de la Camara Gomez, Fernando Busto Fernandez, Maria Mateos Salvador, Margarita Reboredo Lopez
Summary: We evaluated the efficacy and safety of trifluridine/tipiracil (TAS-102) plus bevacizumab in treating refractory metastatic colorectal cancer (mCRC) in a retrospective, observational study. The results showed that this treatment regimen demonstrated certain efficacy in patients and had a good safety profile.
SCIENTIFIC REPORTS
(2022)
